<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR11">
 <label>11.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Yau</surname>
    <given-names>T</given-names>
   </name>
   <name>
    <surname>Kang</surname>
    <given-names>Y-K</given-names>
   </name>
   <name>
    <surname>Kim</surname>
    <given-names>T-Y</given-names>
   </name>
   <name>
    <surname>El-Khoueiry</surname>
    <given-names>AB</given-names>
   </name>
   <name>
    <surname>Santoro</surname>
    <given-names>A</given-names>
   </name>
   <name>
    <surname>Sangro</surname>
    <given-names>B</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Nivolumab (NIVO)+ ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): results from CheckMate 040</article-title>
  <source>J Clin Oncol</source>
  <year>2019</year>
  <volume>37</volume>
  <issue>suppl_15</issue>
  <fpage>4012</fpage>
  <pub-id pub-id-type="doi">10.1200/JCO.2019.37.15_suppl.4012</pub-id>
 </element-citation>
</ref>
